ALOPEXX ENTERPRISES
Alopexx partners with innovative entrepreneurs to build successful new companies. We will in-license novel therapies or medical devices
ALOPEXX ENTERPRISES
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2011-01-01
Address:
Concord, Massachusetts, United States
Country:
United States
Website Url:
http://www.alopexx.com
Total Employee:
11+
Status:
Active
Contact:
978-341-8183
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Domain Not Resolving Apache Microsoft Exchange Online Amazon
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-12-15 | Cognoptix | Alopexx Enterprises investment in Venture Round - Cognoptix | 1.3 M USD |
| 2014-09-30 | Cognoptix | Alopexx Enterprises investment in Series D - Cognoptix | 15 M USD |
Official Site Inspections
http://www.alopexx.com Semrush global rank: 5.83 M Semrush visits lastest month: 1.42 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Alopexx Enterprises" on Search Engine
Alopexx (ALPX)
Alopexx seeks to address one of the greatest medical threats facing humanity – the rise of AMR. That is the assessment of the CDC, World Health Organization and virtually every other health authority.See details»
Alopexx Enterprises - Org Chart, Teams, Culture & Jobs | The Org
View Alopexx Enterprises' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Management Team :: Alopexx (ALPX)
Overview. Management Team. Scientific Advisory Board. Board of Directors. Daniel R Vlock, MD. Co-Founder, Chief Executive Officer and Chairman of the Board Designee. Dr. Vlock brings extensive pharmaceutical industry and academic experience in pharmaceutical drug development.See details»
About :: Alopexx (ALPX)
Scientific Advisory Board. Board of Directors. Innovative Immune Approach To Microbial Diseases. Alopexx is a clinical stage biotechnology company developing novel, broad-spectrum immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections.See details»
Alopexx Enterprises' Leadership Team - The Org
Alopexx Enterprises' Leadership Team. Alopexx Enterprises' Leadership Team includes Daniel R. Vlock and 2 others.See details»
CEO and Executive Team - Team at Alopexx Enterprises - The Org
Alopexx Enterprises' CEO and Executive Team includes Daniel R. Vlock and 2 others.See details»
Alopexx Enterprises' Board of Directors Team - The Org
About. Alopexx Enterprises' Board of Directors includes Gerald B. Pier and 7 others. Team members. Ann MacDougall. Board Member. David Skurnik. Board Member. Gerald B. Pier. Board Member. Peter Honig. Board Member. Peter J. Werth. Board Member. Richard M Cohen. Board Member. William W. Chin. Board Member. Other teams at Alopexx …See details»
Alopexx Enterprises, LLC | LinkedIn
About us. Alopexx Enterprises works with scientists and entrepreneurs to build successful new companies. We invest in novel health care technologies at all stages of development and can serve...See details»
Pipeline :: Alopexx (ALPX)
Pipeline Summary. The 2 immune therapeutics developed by Alopexx have both completed phase 1 clinical trials. They provide distinct approaches to the prevention of infectious diseases. As with Covid, a vaccine and an antibody have different roles to play. The antibody provides immediate but time limited protection.See details»
Alopexx Company Profile - Craft
Alopexx (ALPX, also known as Alopexx Enterprises) is a clinical-stage biotechnology company developing broad-spectrum immune-mediated therapeutics for the prevention, treatment, and mitigation of a wide range of bacterial, fungal, …See details»
Daniel R. Vlock - CEO at Alopexx Enterprises | The Org
Alopexx Enterprises. Daniel R. Vlock. CEO at Alopexx Enterprises. Contact. Join to edit. About. Dr. Vlock brings extensive pharmaceutical industry and academic experience in pharmaceutical drug development. As CEO of Alopexx Pharmaceuticals he and his co-founder Dr. Gerald Pier developed F598, a human monoclonal antibody directed against …See details»
Alopexx - Crunchbase Company Profile & Funding
Details. Industries. Biotechnology. Health Care. Medical. Pharmaceutical. Headquarters Regions Greater Boston Area, East Coast, New England. Founded Date 2011. Founders Daniel Vlock. Operating Status Active. Company Type For Profit. Contact Email [email protected]. Phone Number 978-341-8183. Lists Featuring This Company.See details»
Daniel Vlock - Founder and CEO @ Alopexx - Crunchbase
Sep 30, 2015 Overview. Dr. Vlock is founder and CEO of Alopexx Enterprises, LLC, a healthcare company focused on investing and developing preclinical and early clinical compounds. He is also CEO of Alopexx Pharmaceuticals, which developed a human monoclonal antibody directed against S. aureus.See details»
Alopexx Raises $15m In IPO, Ambition To Drive Blockbuster …
Oct 11, 2022 Edmund Ingham. Investing Group Leader. Summary. Alopexx' IPO will take place on 12th October. The tiny biotech is working on two assets targeting the PNAG polysaccharide, which may impact the...See details»
Alopexx - Contacts, Employees, Board Members, Advisors & Alumni
Alopexx partners with innovative entrepreneurs to build successful new companies. We will in-license novel therapies or medical devicesSee details»
Therapeutic Solutions :: Alopexx (ALPX)
We are a clinical stage biotechnology company focusing on developing novel, broad-spectrum immune-mediated therapeutics for the prevention, treatment and mitigation of a wide range of bacterial, fungal and parasitic microbial infections.See details»
Alopexx - Funding, Financials, Valuation & Investors - Crunchbase
Organization. Alopexx. Connect to CRM. Save. Summary Financials People Technology Signals & News Similar Companies. Highlights. Lead Investments 1. Investments 2. …See details»
Sanofi-Aventis And U.S Biotechnology Company Alopexx Enter …
Dec 10, 2009 Alopexx will receive an upfront payment and research funding from sanofi-aventis and is eligible for development, regulatory and commercial milestone payments which could reach $375 million in...See details»
Contact :: Alopexx (ALPX)
Alopexx. 186 Alewife Brook Pkwy #1068. Cambridge, MA 02138. Email. info @alopexx.com. General Inquiries.See details»
Alopexx completes first-in-man trial of its novel, broad-spectrum …
Oct 25, 2017 Alopexx Vaccine LLC, part of the Alopexx Enterprises portfolio of companies, specializes in the development of vaccines against a range of pathogens and infections. For more information...See details»